Core Points - Evommune, Inc. has filed a registration statement for an initial public offering (IPO) of its common stock, offering 9,375,000 shares at an expected price between $15.00 and $17.00 per share [1] - The company plans to grant underwriters a 30-day option to purchase an additional 1,406,250 shares in connection with the IPO [1] - Evommune's common stock is expected to be listed on the New York Stock Exchange under the symbol "EVMN" [1] - The registration statement is anticipated to become effective on November 5, 2025, allowing the company to price the offering shortly thereafter [1] - Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering [2] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting chronic inflammatory diseases [5] - The company's mission is to enhance patients' daily lives and mitigate long-term effects of uncontrolled inflammation caused by existing therapy limitations [5] - Evommune is advancing a portfolio of differentiated product candidates aimed at addressing key drivers of chronic inflammation [5]
Evommune Announces Commencement of Initial Public Offering